VRNA

Verona Pharma PLC is a London-based clinical-stage biopharmaceutical company dedicated to developing innovative therapies for respiratory diseases with high unmet medical needs. Its lead candidate, ensifentrine, functions as a dual inhibitor targeting dipeptidyl peptidase I and neutrophil elastase, aimed at enhancing lung function in patients suffering from chronic obstructive pulmonary disease (COPD) and asthma. With a strong pipeline focused on respiratory therapeutics, Verona Pharma is strategically positioned to address significant healthcare challenges, making it an attractive investment for institutional stakeholders looking to support advancements in biopharmaceutical solutions.